dpp4i and glp 1 agonist Dipeptidyl peptidase-4 inhibitor Therapeutic Effects of GLP-1 Receptor

[DOI] [PMC free article] [PubMed] [Google Scholar] 106.Wang T, Lu W, Tang H, et al

A.HashimotoR.KunugiH.HattoriK.HayakawaK.et al

article/pii/S0753332224000313 Kelkar, R., et al

Stacking GLP-1 agonists with other appetite suppressants like phentermine increases side effect risk without clear additive benefit

Among people with no prior substance use disorder, those taking GLP-1 drugs had an 18% lower risk of developing alcohol use disorder, a 25% lower risk of opioid use disorder and an approximately 20% lower risk of cocaine and nicotine dependence

Lastly, we provide evidence that the mGIPR-Ab/GLP-1 peptideantibody conjugate accesses the CNS via the CVOs and activates neural pathways involved in regulating food intake and metabolism to induce weight loss